Full name
"VYGON POLSKA" SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
uses securityreCAPTCHA
"VYGON POLSKA" SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
UL. FRANCUSKA 39 / 6, 03-905 WARSZAWA
TAX ID1130093549
Rate company:
"VYGON POLSKA" SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
TAX ID1130093549
KRS0000055645
Share capital149,435.00 zł
address
UL. FRANCUSKA 39 / 6, 03-905 WARSZAWA
Categories
Main category
Is this your company?Update company information to get new customers, get notified of new reviews, and more!
Register Data
NIP
1130093549
REGON
010784130
KRS
0000055645
Legal form
limited liability company
Register Address
UL. FRANCUSKA 39 / 6, 03-905 WARSZAWA
Date of registration in KRS
2001-10-24
Date of commencement of economic activity
2001-10-24
Act signature
WA.XIV NS-REJ.KRS/60208/24/466/ADE
Pkd codes
46.46.Z - Wholesale trade of pharmaceutical and medical products
33.13.Z - Repair and maintenance of electronic and optical devices
33.14.Z - Repair and maintenance of electrical devices
47.73.Z - Retail sale of pharmaceutical products
47.74.Z - Retail sale of medical and orthopedic products
70.22.Z - Head office activities and management consultancy
Financial data
Net sales [PLN]
Gross profit / loss [PLN]
Automatically generated based on financial statements from KRS Registry
| 2021 | 2022 | 2023 | ||
|---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss)  | 1,5 | 2,3 | 2,3 | -0,3 |
EBITDA | 1,4 | 2,3 | 2,2 | -5,2 |
Short time liabilities | 9,8 | 10,1 | 10,3 | 2,3 |
Equity capital | 2,6 | 4,3 | 5,9 | 39,3 |
Operating profit (EBIT) | 1,4 | 2,3 | 2,1 | -5,3 |
Assets | 12,4 | 14,3 | 16,3 | 13,4 |
Net profit (loss) | 1,3 | 1,8 | 1,7 | -7,1 |
Cash | 1,1 | 0,8 | 2,3 | 201,2 |
Net income from sale | 18,2 | 21,3 | 28,1 | 32,1 |
Liabilities and provisions for liabilities | 9,9 | 10,1 | 10,3 | 2,5 |
Working assets | 11,9 | 13,7 | 15,8 | 14,8 |
Depreciation | 0,1 | 0,1 | 0,1 | -1,7 |
% | % | % | p.p. | |
Profitability of capital | 50,9 | 42,3 | 28,2 | -14,1 |
Equity capital to total assets | 20,7 | 29,7 | 36,5 | 6,8 |
Gross profit margin | 8,1 | 11 | 8,3 | -2,7 |
EBITDA Margin | 7,9 | 11 | 7,9 | -3,1 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 197 | 173 | 134 | -39 |
Current financial liquidity indicator | 1.2099487781524658 | 1.3623234033584595 | 1.5292563438415527 | 0,1 |
Net dept to EBITDA | -0.689972996711731 | -0.32924556732177734 | -1.0454721450805664 | -0,7 |
Financial statements
01-01-2023 - 31-12-2023
Annual financial report
Download xades01-01-2023 - 31-12-2023
Annual financial report
Download pdf01-01-2023 - 31-12-2023
Activity report
Download pdf01-01-2023 - 31-12-2023
Resolution on profit distribution or loss coverage
Download pdf01-01-2023 - 31-12-2023
Auditor's opinion / report on the audit of the annual financial statements
Download pdf01-01-2023 - 31-12-2023
Resolution or decision approving the annual financial statements
Download pdfShow more (3)
uses security reCAPTCHA
Opinions
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane
0/ 5.0
How do you rate this company?
Your opinion matters to us.
Companies registered in the same sector
EUR-MED POLSKA
Katowice
NTRADE
Marcinowice
"SOLINEA" sp. z o.o. sp.k.
Ciecierzyn
"MEDILAB" sp. z o.o.
Warszawa
"INSANIX MEDICAL" sp. z o.o.
Kielce
Emprime sp. z o.o.
Sękocin Nowy
CYTOGEN-POLSKA
ŁÓDŹ